Paper37323948
Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis.
Zhu H and 8 others. Int J Nanomedicine, 2023. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis. Papers, record 37323948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37323948
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Triple Negative Breast Neoplasms | Major topic |
| Hyperthermia, Induced | Major topic |
| Female | |
| Humans | |
| Photothermal Therapy | |
| Phototherapy | |
| Tissue Distribution | |
| Immunogenic Cell Death | |
| Doxorubicin |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35787915 | Recent advances in nanoparticle-based photothermal therapy for breast cancer. | J Control Release | 2022 | https://conductscience.org/library/papers/35787915 | PubMed |
| 2 | 32382473 | Emerging Technologies for Real-Time Intraoperative Margin Assessment in Future Breast-Conserving Surgery. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/32382473 | PubMed |
| 3 | 24148240 | Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent. | Biomaterials | 2014 | https://conductscience.org/library/papers/24148240 | PubMed |
| 4 | 33421711 | Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. | Biomaterials | 2021 | https://conductscience.org/library/papers/33421711 | PubMed |
| 5 | 32898630 | Induction of immunogenic cell death of cancer cells through nanoparticle-mediated dual chemotherapy and photothermal therapy. | Int J Pharm | 2020 | https://conductscience.org/library/papers/32898630 | PubMed |
| 6 | 36538368 | Carrier-Free Nanoplatform via Evoking Pyroptosis and Immune Response against Breast Cancer. | ACS Appl Mater Interfaces | 2023 | https://conductscience.org/library/papers/36538368 | PubMed |
| 7 | 36525971 | IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. | Cancer Cell | 2023 | https://conductscience.org/library/papers/36525971 | PubMed |
| 8 | 31350406 | Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. | Nat Commun | 2019 | https://conductscience.org/library/papers/31350406 | PubMed |
| 9 | 35995278 | Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation. | Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35995278 | PubMed |
| 10 | 30346728 | Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine. | Acc Chem Res | 2018 | https://conductscience.org/library/papers/30346728 | PubMed |
| 11 | 34280474 | Progress and challenges of immunotherapy in triple-negative breast cancer. | Biochim Biophys Acta Rev Cancer | 2021 | https://conductscience.org/library/papers/34280474 | PubMed |
| 12 | 32209603 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32209603 | PubMed |
| 13 | 35339668 | Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/35339668 | PubMed |
| 14 | 29178534 | Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? | Angew Chem Int Ed Engl | 2018 | https://conductscience.org/library/papers/29178534 | PubMed |
| 15 | 36385713 | Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial. | J Pineal Res | 2023 | https://conductscience.org/library/papers/36385713 | PubMed |
| 16 | 35447074 | Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. | Cell | 2022 | https://conductscience.org/library/papers/35447074 | PubMed |
| 17 | 36427657 | NIR-triggered ligand-presenting nanocarriers for enhancing synergistic photothermal-chemotherapy. | J Control Release | 2023 | https://conductscience.org/library/papers/36427657 | PubMed |
| 18 | 26348965 | Principles of nanoparticle design for overcoming biological barriers to drug delivery. | Nat Biotechnol | 2015 | https://conductscience.org/library/papers/26348965 | PubMed |
| 19 | 36203955 | An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer. | Bioact Mater | 2023 | https://conductscience.org/library/papers/36203955 | PubMed |
| 20 | 34754128 | Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34754128 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42539503 | Latest advances in nanodrug delivery systems for modulating the immune microenvironment in triple-negative breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42539503 | PubMed |
| 42370175 | Multimodal imaging-guided NIR-II photo-gas nanoplatform amplifies PD-1 blockade for synergistic TNBC therapy. | Theranostics | 2026 | https://conductscience.org/library/papers/42370175 | PubMed |
| 42369649 | Carbon-based nanomaterials in biomedicine and technology. | Front Chem | 2026 | https://conductscience.org/library/papers/42369649 | PubMed |
| 42149294 | Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas. | J Egypt Natl Canc Inst | 2026 | https://conductscience.org/library/papers/42149294 | PubMed |
| 40766970 | Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review. | Front Bioeng Biotechnol | 2025 | https://conductscience.org/library/papers/40766970 | PubMed |
| 40599401 | Advancements in Nano-Delivery Systems for Photodynamic and Photothermal Therapy to Induce Immunogenic Cell Death in Tumor Immunotherapy. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40599401 | PubMed |
| 39725974 | Spatiotemporal-controllable ROS-responsive camptothecin nano-bomb for chemo/photo/immunotherapy in triple-negative breast cancer. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39725974 | PubMed |
| 39325106 | Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects. | Clin Exp Med | 2024 | https://conductscience.org/library/papers/39325106 | PubMed |
| 38815129 | Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer. | ACS Biomater Sci Eng | 2024 | https://conductscience.org/library/papers/38815129 | PubMed |
| 38774648 | Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/38774648 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37323948
GET https://conductscience.org/api/papers/v1/37323948/references?page=2